CHALFONT ST. GILES, England--(BUSINESS WIRE)--Data presented at the XXI World Congress of Neurology in Vienna this week suggest that DaTSCAN™ (Ioflupane I 123 Injection) SPECT imaging could add value to current diagnostic tools used by physicians to diagnose patients with dementia with Lewy bodies (DLB) by improving physician’s ability to definitively diagnose the disorder and increase their confidence in so doing. DaTSCAN is GE Healthcare’s radiopharmaceutical indicated for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging.
Help employers find you! Check out all the jobs and post your resume.
